Synthanecin B | 53365-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Synthanecin B
• 英文别名: 2,3-bis-hydroxymethyl-1-methyl-pyrrolidine；[2-(Hydroxymethyl)-1-methylpyrrolidin-3-yl]methanol
• CAS: 53365-60-9
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: KIKZQCGDVSJYKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY
  申请人：Wadman Sjoerd Nicolaas

  公开号：US20100261638A1

  公开（公告）日：2010-10-14

  The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R 1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R 2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R 1 and R 2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, —NR 3 R 4 , —NR 5 COR 6 , —NR 5 C(O)OR 6 ; —NR 5 SOR 6 , NR 5 SO 2 R 6 ; —NR 5 C(S)NR 6 R 7 , —NR 5 C(NR 8 )NR 6 R 7 , or —N═R 9 , where R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R 9 is not hydrogen; and Y is —S— or —S(O)—. The compounds find use in the treatment of microbial infections.
• US8329644B2
  申请人：——

  公开号：US8329644B2

  公开（公告）日：2012-12-11
• [EN] THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY<br/>[FR] UTILISATION DE COMPOSÉS À BASE DE LANTIBIOTIQUE DE TYPE B À ACTIVITÉ ANTIMICROBIENNE
  申请人：NOVACTA BIOSYSTEMS LTD

  公开号：WO2009010763A1

  公开（公告）日：2009-01-22

  The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The type-B lantibiotics may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.
• [EN] LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY<br/>[FR] COMPOSES A BASE DE LANTHIBIOTIQUE A ACTIVITE ANTIMICROBIENNE
  申请人：NOVACTA BIOSYSTEMS LTD

  公开号：WO2009010765A2

  公开（公告）日：2009-01-22

  The present invention provides actagardine, actagradine B and deoxy actagardine B derivatives of formula (I), wherein: X1 denotes that the residue is Leu; Val; or Ile; X2 denotes that the residue is Leu; Val; or Ile; R1 represents an alkyl or heteroalkyl group, substituted by at least one hydroxyl substituent, and R2 represents hydrogen, or an alkyl or heteroalkyl group, optionally substituted by at least one hydroxyl substituent, or R1 and R2 taken together with the nitrogen atom represent a heterocyclic group having at least one hydroxyl substituent, wherein the heterocyclic group optionally further contains one or more heteroatoms; Z is an amino acid residue, -NR3R4, -NR5COR6, -NR5C(O)OR6; -NR5SOR6, NR5SO2 R6; -NR5C(S)NR6R7, -NR5C(NR8)NR6R7, or -N=R9, where R3, R4, R5, R6, R7, R8 and R9 are independently hydrogen, or a group, optionally substituted, selected from alkyl, heteroalkyl, aryl, heteroaryl, aralkyl and heteroaralkyl, with the proviso that R9 is not hydrogen; and Y is -S- or -S(O)-. The compounds find use in the treatment of microbial infections.